BENEFIT OF TRIPLE THERAPY FOR TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARYDISEASEWITH PERSISTENT SYMPTOMSAND REPEATED EXACERBATIONS

Abstract

Chronic obstructive pulmonary disease (COPD) is characterised by persistent respiratory symptoms and airflow limitation that is usually caused by significant exposure to noxious particles or gases. The goals of pharmacological treatment
of COPD are to reduce symptoms and the risk of future exacerbations. Patients with COPD with a history of exacerbations are at an increased risk of future exacerbations, and are more likely to have a reduced quality of life, more rapid lung function
decline, and increasedmortality. Three large-scale clinical trials TRILOGY, TRINITY, and TRIBUTE confirmed the superiority of triple therapy (IVMA + IVBA + iGKS) in patients placed into D group according GOLD (compared to IVMA, ICS/IVBA, ICS/IVMA and IVMA/IVBA). In the post hoc analysis of TRILOGY and TRINITY, triple therapy benefit was also seen in some patients with GOLD B. The possibility to prescribe treatment of all triple therapy active substances in one inhaler is an entirely new treatment option formoderate to severe COPD patientswith persistent symptoms and recurrent exacerbations that provide effective, safe and convenient treatment.